X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KME-0584, is a first in class IRAK1/4/panFIt3 inhibitor investigational drug, which is being developed for the treatment of relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Lead Product(s): KME-0584
Therapeutic Area: Oncology Product Name: KME-0584
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
Kurome is developing a series of potent IRAK1/4 and panFLT3 inhibitors that work by targeting key cancer survival pathways. The company’s first to market indications will be Acute Myeloid Leukemia (AML) and high-risk MDS.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
The funding will support the pre-clinical advancement of dual IRAK1/4 and panFLT3 inhibitors to target cancer cells that evade the effects of both targeted therapy and chemotherapy drugs via adaptive resistance mechanisms.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medicxi
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 10, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
